Accelerated Partial Breast Irradiation: 5-Year Results of the German-Austrian Multicenter Phase II Trial Using Interstitial Multicatheter Brachytherapy Alone After Breast-Conserving Surgery

Journal Article · Sun May 01 04:00:00 EDT 2011 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2010.01.020· OSTI ID:21491734

Strnad, Vratislav ^[1]; Hildebrandt, Guido ^[2]; Poetter, Richard ^[3]; Hammer, Josef ^[4]; Hindemith, Marion ^[2]; Resch, Alexandra ^[3]; Spiegl, Kurt ^[4]; Lotter, Michael ^[1]; Uter, Wolfgang ^[5]; Bani, Mayada ^[6]; Kortmann, Rolf-Dieter ^[2]; Beckmann, Matthias W ^[6]; Fietkau, Rainer; Ott, Oliver J ^[1]

---

1. Department of Radiation Oncology, University Hospital Erlangen, Erlangen (Germany)
2. Department of Radiation Oncology, University Hospital Leipzig, Leipzig (Germany)
3. Department of Radiation Oncology and Radiobiology, University Hospital AKH Vienna, Vienna (Austria)
4. Department of Radiation Oncology, Barmherzige Schwestern Hospital, Linz (Austria)
5. Department for Medical Informatics, Biometry and Epidemiology, University Erlangen-Nuremberg, Erlangen (Germany)
6. Department of Obstetrics and Gynaecology, University Hospital Erlangen, Erlangen (Germany)

Purpose: To evaluate the impact of accelerated partial breast irradiation on local control, side effects, and cosmesis using multicatheter interstitial brachytherapy as the sole method for the adjuvant local treatment of patients with low-risk breast cancer. Methods and Materials: 274 patients with low-risk breast cancer were treated on protocol. Patients were eligible for the study if the tumor size was < 3 cm, resection margins were clear by at least 2 mm, no lymph node metastases existed, age was >35 years, hormone receptors were positive, and histologic grades were 1 or 2. Of the 274 patients, 175 (64%) received pulse-dose-rate brachytherapy (D{sub ref} = 50 Gy). and 99 (36%) received high-dose-rate brachytherapy (D{sub ref} = 32.0 Gy). Results: Median follow-up was 63 months (range, 9-103). Only 8 of 274 (2.9%) patients developed an ipsilateral in-breast tumor recurrence at the time of analysis. The 5-year actuarial local recurrence-free survival probability was 98%. The 5- year overall and disease-free survival probabilities of all patients were 97% and 96%, respectively. Contralateral in-breast malignancies were detected in 2 of 274 (0.7%) patients, and distant metastases occurred in 6 of 274 (2.2%). Late side effects {>=}Grade 3 (i.e., breast tissue fibrosis and telangiectasia) occurred in 1 patient (0.4%, 95%CI:0.0-2.0%) and 6 patients (2.2%, 95%CI:0.8-4.7%), respectively. Cosmetic results were good to excellent in 245 of 274 patients (90%). Conclusions: The long-term results of this prospective Phase II trial confirm that the efficacy of accelerated partial breast irradiation using multicatheter brachytherapy is comparable with that of whole breast irradiation and that late side effects are negligible.

• OSTI ID: 21491734
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 1 Vol. 80; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
BODY
BRACHYTHERAPY
DISEASES
EXTERNAL IRRADIATION
GLANDS
IRRADIATION
MAMMARY GLANDS
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
ORGANS
PARTIAL BODY IRRADIATION
RADIOLOGY
RADIOTHERAPY
SURGERY
THERAPY